newsfilter
← Latest News
GlobeNewswire·

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ALGS
  • Aligos Therapeutics (NASDAQ: ALGS) granted non-qualified stock options for 10,700 shares to newly hired employees on April 22, 2026.
  • The grant, termed the "Inducement Grant," was authorized by the Compensation Committee pursuant to the company's 2024 Inducement Plan & Nasdaq Listing Rule 5635(c)(4).
  • The exercise price per share equals the closing price of Aligos common stock on the Grant Date.
  • Shares subject to the grant vest over four years, with 25% vesting on the first anniversary & the remainder vesting in equal monthly installments contingent on continued employment.
  • The Plan is exclusively used for equity awards to individuals who were not previously employed by Aligos.
  • Aligos is a clinical stage biopharmaceutical company focused on developing therapies for liver & viral diseases, including HBV, MASH, obesity, & coronaviruses.
  • The press release includes forward-looking statements regarding the company's mission & development pipeline, subject to risks inherent in drug development & regulatory approval.
  • Aligos filed its Annual Report on Form 10-K with the SEC on March 5, 2026, & undertakes no obligation to update forward-looking statements.